Research programme: sodium glucose co-transporter type 2 inhibitors - Sirona Biochem

Drug Profile

Research programme: sodium glucose co-transporter type 2 inhibitors - Sirona Biochem

Alternative Names: SBM TFC 039; TFC-039; Wangeliejin

Latest Information Update: 16 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirona Biochem
  • Developer Sirona Biochem; Wanbang Biopharma
  • Class Antihyperglycaemics; Carbohydrates; Obesity therapies
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus
  • No development reported Obesity

Most Recent Events

  • 12 Jul 2018 China FDA approves IND application for initiation of a phase I trial of TFC 039 in Type 2 diabetes mellitus
  • 29 Dec 2017 Wanbang Biopharma files an IND application with the China FDA for Type 2 diabetes mellitus
  • 19 Dec 2017 Wanbang Biopharmaceuticals announces intention to submit an IND application for SBM TFC 039 in China in January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top